JP2011507956A5 - - Google Patents

Download PDF

Info

Publication number
JP2011507956A5
JP2011507956A5 JP2010540673A JP2010540673A JP2011507956A5 JP 2011507956 A5 JP2011507956 A5 JP 2011507956A5 JP 2010540673 A JP2010540673 A JP 2010540673A JP 2010540673 A JP2010540673 A JP 2010540673A JP 2011507956 A5 JP2011507956 A5 JP 2011507956A5
Authority
JP
Japan
Prior art keywords
controlled release
concentration
oral solid
component
solid formulation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2010540673A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011507956A (ja
JP5783725B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2008/014080 external-priority patent/WO2009085306A1/en
Publication of JP2011507956A publication Critical patent/JP2011507956A/ja
Publication of JP2011507956A5 publication Critical patent/JP2011507956A5/ja
Application granted granted Critical
Publication of JP5783725B2 publication Critical patent/JP5783725B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2010540673A 2007-12-28 2008-12-26 レボドパの放出制御製剤及びその使用 Active JP5783725B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US945707P 2007-12-28 2007-12-28
US61/009,457 2007-12-28
PCT/US2008/014080 WO2009085306A1 (en) 2007-12-28 2008-12-26 Controlled release formulations of levodopa and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2015145033A Division JP6033373B2 (ja) 2007-12-28 2015-07-22 レボドパの放出制御製剤及びその使用

Publications (3)

Publication Number Publication Date
JP2011507956A JP2011507956A (ja) 2011-03-10
JP2011507956A5 true JP2011507956A5 (cg-RX-API-DMAC7.html) 2012-02-16
JP5783725B2 JP5783725B2 (ja) 2015-09-24

Family

ID=40824610

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2010540673A Active JP5783725B2 (ja) 2007-12-28 2008-12-26 レボドパの放出制御製剤及びその使用
JP2015145033A Active JP6033373B2 (ja) 2007-12-28 2015-07-22 レボドパの放出制御製剤及びその使用
JP2016208444A Active JP6328205B2 (ja) 2007-12-28 2016-10-25 レボドパの放出制御製剤及びその使用

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2015145033A Active JP6033373B2 (ja) 2007-12-28 2015-07-22 レボドパの放出制御製剤及びその使用
JP2016208444A Active JP6328205B2 (ja) 2007-12-28 2016-10-25 レボドパの放出制御製剤及びその使用

Country Status (12)

Country Link
US (8) US8377474B2 (cg-RX-API-DMAC7.html)
EP (1) EP2234963B1 (cg-RX-API-DMAC7.html)
JP (3) JP5783725B2 (cg-RX-API-DMAC7.html)
KR (3) KR101569604B1 (cg-RX-API-DMAC7.html)
CN (1) CN101910113A (cg-RX-API-DMAC7.html)
AU (1) AU2008343787B2 (cg-RX-API-DMAC7.html)
CA (1) CA2711014C (cg-RX-API-DMAC7.html)
IL (3) IL206756A (cg-RX-API-DMAC7.html)
MX (1) MX2010007207A (cg-RX-API-DMAC7.html)
NZ (2) NZ602302A (cg-RX-API-DMAC7.html)
WO (1) WO2009085306A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201005309B (cg-RX-API-DMAC7.html)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ602302A (en) 2007-12-28 2014-04-30 Impax Laboratories Inc Controlled release formulations of levodopa and uses thereof
US20110166370A1 (en) 2010-01-12 2011-07-07 Charles Winston Saunders Scattered Branched-Chain Fatty Acids And Biological Production Thereof
WO2012054815A1 (en) 2010-10-22 2012-04-26 Duke University Slow-release formulations of 5-hydroxytryptophan as an adjunct to pro-serotonergic therapies
WO2013035053A2 (en) * 2011-09-09 2013-03-14 Kareus Therapeutics, Sa Novel conjugation-facilitated transport of drugs across blood brain barrier
WO2014006571A2 (en) * 2012-07-02 2014-01-09 Ranbaxy Laboratories Limited Extended-release pharmaceutical dosage forms of carbidopa and levodopa and processes of preparation thereof
WO2014066206A1 (en) * 2012-10-22 2014-05-01 Civitas Therapeutics , Inc. Reducing inter-patient variability of levodopa plasma concentrations
US20140150787A1 (en) * 2012-12-04 2014-06-05 Civitas Therapeutics, Inc. Devices and methods for puncturing a capsule to release a powdered medicament therefrom
US9468681B2 (en) 2013-03-01 2016-10-18 California Institute Of Technology Targeted nanoparticles
US10510914B2 (en) 2013-03-21 2019-12-17 Board Of Trustees Of Michigan State University Transparent energy-harvesting devices
CN103417494B (zh) * 2013-08-13 2015-12-23 杭州高成生物营养技术有限公司 一种以酒石酸作为主要成分的微丸
CN105658211A (zh) * 2013-10-07 2016-06-08 怡百克制药公司 左旋多巴和/或左旋多巴的酯的粘膜粘附性、控制释放调配物和其用途
US10987313B2 (en) 2013-10-07 2021-04-27 Impax Laboratories, Llc Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof
EP3317323B1 (en) 2015-07-01 2021-05-26 California Institute of Technology Cationic mucic acid polymer-based delivery systems
EP3184101A1 (en) 2015-12-21 2017-06-28 Sandoz Ag Levodopa and carbidopa modified release composition
CN109689036B (zh) 2016-07-11 2026-06-19 康特拉医药股份有限公司 用于治疗早晨运动不能的脉冲药物输送系统
US10736905B1 (en) 2016-09-09 2020-08-11 Shahin Fatholahi Nefopam dosage forms and methods of treatment
JP7066351B2 (ja) * 2017-08-18 2022-05-13 大原薬品工業株式会社 良好な徐放性を有する、レボドパ含有小型化錠剤
US10736874B1 (en) 2017-09-08 2020-08-11 Shahin Fatholahi Methods for treating pain associated with sickle cell disease
US11446311B2 (en) 2017-09-08 2022-09-20 Shahin Fatholahi Methods for treating pain associated with sickle cell disease
CN111526872B (zh) 2018-02-28 2022-05-17 上海汉都医药科技有限公司 一种药物组合物及其制备方法和应用
WO2019217583A1 (en) 2018-05-09 2019-11-14 Board Of Trustees Of Michigan State University Near-infrared harvesting transparent luminescent solar concentrators with engineered stokes shift
EP3797818B1 (en) 2018-05-23 2023-01-18 Shanghai WD Pharmaceutical Co., Ltd Controlled-release system of active pharmaceutical ingredient and preparation method therefor
US11911513B2 (en) 2018-05-23 2024-02-27 Shanghai Wd Pharmaceutical Co., Ltd Controlled-release system of active pharmaceutical ingredient and preparation method therefor
US20190381188A1 (en) 2018-06-13 2019-12-19 California Institute Of Technology Nanoparticles For Crossing The Blood Brain Barrier And Methods Of Treatment Using The Same
JP2021532098A (ja) 2018-07-19 2021-11-25 インペル ニューロファーマ インコーポレイテッド パーキンソン病の治療のためのレボドパおよびドーパデカルボキシラーゼ阻害剤の呼吸管路送達
WO2020068670A1 (en) 2018-09-24 2020-04-02 Board Of Trustees Of Michigan State University Transparent luminescent solar concentrator
US11698461B1 (en) 2019-11-20 2023-07-11 Telephonics Corp. GPS denial detection and reporting and mitigation
CN111701024B (zh) * 2020-05-26 2022-05-24 上海京新生物医药有限公司 一种左旋多巴制剂及其制备方法及其应用
US12194150B2 (en) 2020-12-22 2025-01-14 Amneal Pharmaceuticals Llc Levodopa dosing regimen
US11986449B2 (en) 2020-12-22 2024-05-21 Amneal Pharmaceuticals Llc Levodopa dosing regimen
CN114681392A (zh) * 2020-12-29 2022-07-01 江苏恒瑞医药股份有限公司 一种缓释口服固体组合物
CN114762684B (zh) * 2021-01-14 2023-11-21 华益泰康药业股份有限公司 一种治疗帕金森的缓释胶囊及其制备方法
CN113616621B (zh) * 2021-08-19 2025-03-14 北京世桥生物制药有限公司 一种左旋多巴和卡比多巴控释制剂及其制备方法
WO2025032501A1 (en) * 2023-08-08 2025-02-13 Alembic Pharmaceuticals Limited Pharmaceutical composition comprising combination of levodopa and carbidopa
US12303604B1 (en) 2024-10-16 2025-05-20 Currax Pharmaceuticals Llc Pharmaceutical formulations comprising naltrexone and/or bupropion

Family Cites Families (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3891696A (en) 1973-11-02 1975-06-24 Interx Research Corp Novel, transient pro-drug forms of l-dopa
FR2470599A1 (fr) 1979-12-07 1981-06-12 Panoz Donald Perfectionnements apportes aux procedes de preparation de formes galeniques a action retard et a liberation programmee et formes galeniques de medicaments ainsi obtenus
DE3000979A1 (de) 1980-01-12 1981-07-23 Dr. Karl Thomae Gmbh, 7950 Biberach Neue dipyridamol-retardformen und verfahren zu ihrer herstellung
DE3124090A1 (de) 1981-06-19 1983-01-05 Dr. Karl Thomae Gmbh, 7950 Biberach Neue orale dipyridamolformen
DE3126703A1 (de) 1981-07-07 1983-01-27 Dr. Karl Thomae Gmbh, 7950 Biberach Bromhexin-retardform und verfahren zu ihrer herstellung
US4849227A (en) 1986-03-21 1989-07-18 Eurasiam Laboratories, Inc. Pharmaceutical compositions
DE3779500T2 (de) 1986-06-10 1993-01-21 Chiesi Farma Spa Levodopa-methyl-ester enthaltende pharmazeutische zusammensetzungen, ihre herstellung und therapeutische verwendungen.
ZA889189B (en) 1986-06-16 1989-08-30 Merck & Co Inc Controlled release combination of carbidopa/levodopa
NZ220599A (en) 1986-06-16 1990-10-26 Merck & Co Inc Controlled release oral dosage formulation of carbidopa and levodopa
US4832957A (en) 1987-12-11 1989-05-23 Merck & Co., Inc. Controlled release combination of carbidopa/levodopa
JP2782691B2 (ja) 1987-09-29 1998-08-06 ワーナー−ランバート・コンパニー 腸溶製剤の安定化
US4938968A (en) 1988-07-26 1990-07-03 Norjec Development Associates, Inc. Controlled release indomethacin
IT1229856B (it) 1989-04-20 1991-09-13 Recordati Chem Pharm Compresse a rilascio controllato contenenti flavossato.
IE66933B1 (en) 1990-01-15 1996-02-07 Elan Corp Plc Controlled absorption naproxen formulation for once-daily administration
US5624960A (en) 1991-01-23 1997-04-29 Isis Pharma Gmbh Orally administrable drugs for the treatment of central dopamine deficiency conditions
DE4101873C2 (de) 1991-01-23 1993-12-09 Isis Pharma Gmbh Peroral applizierbare Arzneiform zur Behandlung zentraler Dopaminmangelzustände
IT1255522B (it) 1992-09-24 1995-11-09 Ubaldo Conte Compressa per impiego terapeutico atta a cedere una o piu' sostanze attive con differenti velocita'
IT1264696B1 (it) 1993-07-09 1996-10-04 Applied Pharma Res Forme farmaceutiche destinate alla somministrazione orale in grado di rilasciare sostanze attive a velocita' controllata e differenziata
EP0711166A1 (en) 1993-07-22 1996-05-15 Warner-Lambert Company Controlled release tacrine drug delivery systems and methods for preparing same
SG80553A1 (en) 1995-07-20 2001-05-22 Tanabe Seiyaku Co Pharmaceutical preparation in form of coated capsule releasable at lower part of digestive tract
US5840756A (en) 1995-07-21 1998-11-24 Teva Pharmaceutical Industries Ltd. Pharmaceutical composition of L-DOPA ester
AUPN605795A0 (en) 1995-10-19 1995-11-09 F.H. Faulding & Co. Limited Analgesic pharmaceutical composition
IT1282576B1 (it) 1996-02-06 1998-03-31 Jagotec Ag Compressa farmaceutica atta a cedere la sostanza attiva in tempi successivi e predeterminabili
US5773031A (en) 1996-02-27 1998-06-30 L. Perrigo Company Acetaminophen sustained-release formulation
US5788987A (en) * 1997-01-29 1998-08-04 Poli Industria Chimica Spa Methods for treating early morning pathologies
US6756056B2 (en) 1997-04-08 2004-06-29 Alan A. Rubin Treatment of Parkinson's disease and related disorders by novel formulations of the combination carbidopa-levodopa
IT1293764B1 (it) 1997-07-23 1999-03-10 Chiesi Farma Spa Composizioni farmaceutiche sotto forma di compresse effervescenti contenenti un principio attivo instabile in presenza di acqua
US6372254B1 (en) 1998-04-02 2002-04-16 Impax Pharmaceuticals Inc. Press coated, pulsatile drug delivery system suitable for oral administration
WO2000015197A1 (en) 1998-09-14 2000-03-23 Rubin Alan A Improvement in treatment of parkinson's disease and related disorders by novel formulations of the combination carbidopa-levodopa
IL142896A0 (en) 1998-11-02 2002-04-21 Elan Corp Plc Multiparticulate modified release composition
DE69915346T2 (de) 1998-12-17 2004-07-22 Alza Corp., Mountain View Umwandlung von flüssigkeitsgefüllten gelatinkapseln in systeme mit gesteuerter wirkstoffabgabe durch mehrfache beschichtungen
US6627223B2 (en) 2000-02-11 2003-09-30 Eurand Pharmaceuticals Ltd. Timed pulsatile drug delivery systems
US6372252B1 (en) 2000-04-28 2002-04-16 Adams Laboratories, Inc. Guaifenesin sustained release formulation and tablets
US6531153B2 (en) 2001-05-29 2003-03-11 Drugtech Corporation Composition with sustained release of levodopa and carbidopa
US20040028613A1 (en) 2001-06-25 2004-02-12 Nastech Pharmaceutical Company Inc Dopamine agonist formulations for enhanced central nervous system delivery
IL159812A0 (en) 2001-07-12 2004-06-20 Teva Pharma Dual release formulation comprising levodopa ethyl ester and a decarboxylase inhibitor in immediate release layer with levodopa ethyl ester in a controlled release core
IL159813A0 (en) 2001-07-12 2004-06-20 Teva Pharma Dual release formulation comprising levodopa ethyl ester and a decarboxylase inhibitor in immediate release layer with levodopa ethyl ester and a decarboxylase inhibitor in a controlled release core
US6811794B2 (en) 2001-12-20 2004-11-02 Shire Laboratories, Inc. Sustained release pharmaceutical dosage forms with minimized pH dependent dissolution profiles
US7094427B2 (en) 2002-05-29 2006-08-22 Impax Laboratories, Inc. Combination immediate release controlled release levodopa/carbidopa dosage forms
US20040166159A1 (en) 2002-05-29 2004-08-26 Chien-Hsuan Han Pharmaceutical dosage forms having immediate and controlled release properties that contain an aromatic amino acid decarboxylase inhibitor and levodopa
US20030224045A1 (en) 2002-05-29 2003-12-04 Chien-Hsuan Han Combination immediate release sustained release levodopa/carbidopa dosage forms
US20060013875A1 (en) 2002-05-29 2006-01-19 Impax Laboratories, Inc. Combination immediate release controlled release levodopa/carbidopa dosage forms
US20050147670A1 (en) 2002-05-29 2005-07-07 Impax Laboratories Inc. Oral disintegrating dosage forms
WO2004082615A2 (en) * 2003-03-14 2004-09-30 Nirmal Mulye A process for preparing sustained release tablets
MXPA06002344A (es) * 2003-08-29 2006-05-19 Transform Pharmaceuticals Inc Composiciones farmaceuticas y metodo para usar levodopa y carbidopa.
US8815950B2 (en) * 2003-08-29 2014-08-26 Janssen Biotech, Inc. Pharmaceutical compositions and method of using levodopa and carbidopa
WO2006026556A2 (en) 2004-08-27 2006-03-09 Spherics, Inc. Bioadhesive rate-controlled oral dosage formulations
JP4188263B2 (ja) 2004-03-01 2008-11-26 ミツヤゴルフ株式会社 多用途利用可能なレール構造
US8007827B2 (en) 2004-04-02 2011-08-30 Impax Laboratories, Inc. Pharmaceutical dosage forms having immediate release and/or controlled release properties
WO2005099678A1 (en) 2004-04-06 2005-10-27 Transform Pharmaceuticals, Inc. Pharmaceutical compositions and method of using levodopa and carbidopa
US20070281007A1 (en) * 2004-08-27 2007-12-06 Jacob Jules S Mucoadhesive Oral Formulations of High Permeability, High Solubility Drugs
US20060045865A1 (en) * 2004-08-27 2006-03-02 Spherics, Inc. Controlled regional oral delivery
AU2006228296B2 (en) * 2005-03-28 2011-08-04 Orexo Ab New pharmaceutical compositions useful in the treatment of Parkinson's disease
US7803817B2 (en) * 2005-05-11 2010-09-28 Vecta, Ltd. Composition and methods for inhibiting gastric acid secretion
EP1901720A2 (en) * 2005-06-23 2008-03-26 Spherics, Inc. Improved dosage forms for movement disorder treatment
EP1901721A1 (en) 2005-06-23 2008-03-26 Spherics, Inc. Delayed release or extended-delayed release dosage forms of pramipexole
US20070275060A1 (en) 2005-08-05 2007-11-29 Osmotica Costa Rica Sociedad Anonima Extended release solid pharmaceutical composition containing carbidopa and levodopa
RU2442574C2 (ru) 2005-08-22 2012-02-20 Новартис Аг ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ, СОДЕРЖАЩИЕ pН-ЗАВИСИМОЕ ЛЕКАРСТВЕННОЕ СРЕДСТВО, МОДИФИКАТОР pН И ЗАМЕДЛЯЮЩИЙ АГЕНТ
WO2007072911A1 (ja) 2005-12-22 2007-06-28 Asubio Pharma Co., Ltd. 塩酸サプロプテリンの生体内吸収性を向上させた製剤
JP5433236B2 (ja) 2006-01-27 2014-03-05 アプタリス ファーマテック,インコーポレイテッド 弱塩基性選択性セロトニン5−ht3遮断剤および有機酸を含む薬物送達系
US20070196491A1 (en) 2006-01-27 2007-08-23 Eurand, Inc. Drug delivery systems comprising weakly basic drugs and organic acids
US8637080B2 (en) 2007-06-28 2014-01-28 Osmotica Kereskedelmi és Szolgáltató, KFT Rupturing controlled release device comprising a subcoat
NZ602302A (en) 2007-12-28 2014-04-30 Impax Laboratories Inc Controlled release formulations of levodopa and uses thereof
CA2789236C (en) 2009-11-09 2014-09-09 Xenoport, Inc. Pharmaceutical compositions and oral dosage forms of a levodopa prodrug and methods of use
EP2508174A1 (en) 2011-04-06 2012-10-10 Ljiljana Sovic Brkicic Pharmaceutical composition
US20130195973A1 (en) 2012-01-30 2013-08-01 Ranbaxy Laboratories Limited Extended release pharmaceutical dosage forms of carbidopa and levodopa and process of preparation thereof
CN105658211A (zh) 2013-10-07 2016-06-08 怡百克制药公司 左旋多巴和/或左旋多巴的酯的粘膜粘附性、控制释放调配物和其用途

Similar Documents

Publication Publication Date Title
JP7398999B2 (ja) 薬物動態が改善された放出調節ガンマ-ヒドロキシ酪酸塩製剤
US20220071929A1 (en) Application of r-ketamine and salt thereof as pharmaceuticals
JP5783725B2 (ja) レボドパの放出制御製剤及びその使用
JP2019048843A5 (cg-RX-API-DMAC7.html)
JP2011502997A5 (cg-RX-API-DMAC7.html)
JP2013521310A5 (cg-RX-API-DMAC7.html)
JP2008540394A5 (cg-RX-API-DMAC7.html)
JP2015526458A5 (cg-RX-API-DMAC7.html)
EP3831382A1 (en) Administration regime for nitrocatechols
JP2015504871A5 (cg-RX-API-DMAC7.html)
KR20110046554A (ko) 엔타카폰 또는 이의 염의 서방형 약학 조성물
JP2019116494A (ja) アカンプロサート製剤、それを用いる方法、およびそれを含む合剤
JP6704252B2 (ja) 位置特異的非対称重水素富化カテコールアミン誘導体および前記化合物を含有する医薬
JP2022502492A5 (cg-RX-API-DMAC7.html)
JP2006517232A5 (cg-RX-API-DMAC7.html)
JP2017536380A (ja) 15−hepeを含む組成物、およびそれを用いて線維症を処置または防止する方法
JP2008519811A (ja) 下肢静止不能症候群の治療
JP2009507048A5 (cg-RX-API-DMAC7.html)
JP2007520488A5 (cg-RX-API-DMAC7.html)
JP2014513130A5 (cg-RX-API-DMAC7.html)
MX2011002016A (es) Composición farmacéutica de dosis oral en una sola unidad, que comprende levodopa, carbidopa y entacapona, o sales.
JP2014531470A5 (cg-RX-API-DMAC7.html)
JP2018529747A5 (cg-RX-API-DMAC7.html)
MA et al. Clonidine, moxonidine, folic acid, and mecobalamin improve baroreflex function in stroke‐prone, spontaneously hypertensive rats
FI3777842T3 (fi) Melatoniinin minitabletteja ja menetelmä niiden valmistamiseksi